Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K
Disorders of Leukocytes01:27

Disorders of Leukocytes

2.1K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.1K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.1K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.1K
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

950
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
950
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

768
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
768

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Driving treatment for females with X-linked adrenoleukodystrophy.

Molecular genetics and metabolism·2026
Same author

Risk of Seizures and Epilepsy in the Leukodystrophies.

Pediatric neurology·2025
Same author

Loss of peroxisome function promotes oxidative stress-induced hematopoiesis.

Stem cells (Dayton, Ohio)·2025
Same author

Vitamin D status and latitude predict brain lesions in adrenoleukodystrophy.

Annals of the Child Neurology Society·2024
Same author

A Phase 1 Study of Oral Vitamin D<sub>3</sub> in Boys and Young Men With X-Linked Adrenoleukodystrophy.

Neurology. Genetics·2023
Same author

International Recommendations for the Diagnosis and Management of Patients With Adrenoleukodystrophy: A Consensus-Based Approach.

Neurology·2022
Same journal

Correction to: Recent Structural Insights into the Molecular Architecture of Synapses.

Advances in neurobiology·2026
Same journal

Roles of Glia in Synapse Nano-organization.

Advances in neurobiology·2026
Same journal

Visualizing Postsynaptic Density in Excitatory Synapses with Electron Tomography.

Advances in neurobiology·2026
Same journal

Optical Approaches to Dissect the Structure and Dynamics of the Synapse at Nanoscale Resolution.

Advances in neurobiology·2026
Same journal

Functional Nano-segregation of Distinct Forms of Neurotransmission.

Advances in neurobiology·2026
Same journal

Scales of Postsynaptic Nanostructure: Molecules, Nanoclusters, and Nanodomains.

Advances in neurobiology·2026
See all related articles

Related Experiment Video

Updated: Feb 27, 2026

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
07:45

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

Published on: October 21, 2014

8.4K

Leukodystrophy: Basic and Clinical.

Gerald V Raymond1,2

  • 1Pediatric Neurology, University of Minnesota Medical Center, Minneapolis, MN, 55455, USA. gvraymon@umn.edu.

Advances in Neurobiology
|July 5, 2017
PubMed
Summary
This summary is machine-generated.

Leukodystrophies are genetic disorders affecting CNS myelin. Advances in neuroimaging and genetic tools are improving diagnosis and understanding of these progressive conditions, paving the way for targeted therapies.

Keywords:
AdrenoleukodystrophyAlexander diseaseGloboid cell leukodystrophyLeukodystrophyMyelin

More Related Videos

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.3K
Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.6K

Related Experiment Videos

Last Updated: Feb 27, 2026

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
07:45

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

Published on: October 21, 2014

8.4K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.3K
Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.6K

Area of Science:

  • Neuroscience
  • Genetics
  • Neurology

Background:

  • Leukodystrophies are severe, progressive, genetic disorders impacting the central nervous system's (CNS) myelin.
  • These conditions arise from abnormalities in oligodendrocytes or associated supporting cells and tissues.
  • Recent advancements in neuroimaging are increasing the detection of leukodystrophies, even in unexpected cases.

Purpose of the Study:

  • To highlight the increasing recognition of leukodystrophies due to advancements in diagnostic technologies.
  • To emphasize the role of new genetic tools in improving the diagnosis of these disorders.
  • To discuss the evolving understanding of leukodystrophy pathogenesis and its implications for future therapies.

Main Methods:

  • Review of recent developments in neuroimaging techniques for detecting CNS myelin disorders.
  • Analysis of the impact of new genetic tools on the diagnostic capabilities for leukodystrophies.
  • Synthesis of current knowledge on the pathogenesis of leukodystrophies.

Main Results:

  • Neuroimaging advancements are leading to increased identification of leukodystrophies.
  • Improved genetic diagnostic tools are enhancing the ability to identify specific leukodystrophy types.
  • Understanding of the underlying disease mechanisms is progressively improving.

Conclusions:

  • Leukodystrophies are increasingly recognized due to technological progress in diagnostics.
  • Enhanced understanding of pathogenesis is crucial for developing targeted therapeutic strategies.
  • Future research is expected to yield more effective treatments for these devastating genetic disorders.